Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Bendamustine in Relapsed/Refractory Multiple Myeloma
NCT01315873Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Sep 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine in multiple myeloma (MM), sponsored by NYU Langone Health. Started Sep 2011; status: terminated.
02
Drugs
bendamustine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01315873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315873.